Thursday, March 10, 2022 9:13:03 PM
They won't be able to pay it off becasue they haven't even entered clinical trials, and those take a long time and after that they have to get appproval of the drugs etc. there is no way they can do that within a year.
They simply won't generate revenue and therefore this will get diluted into trips.
I have called 2-3 cents share price in march and we have alrdy been there today and now I am calling trips within this year, watch.
Now we know why they approved R/S... they are gonna dilute this POS, RS and do it all over again
trips unless miracle happens.
Recent CUBT News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/06/2024 09:31:41 PM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM